Upon completion of feeding, the mosquito withdraws her proboscis, and as the gut fills up, the stomach lining secretes a peritrophic membrane that surrounds the blood. This membrane keeps the blood separate from anything else in the stomach. Like many Hemiptera and other insects that survive on dilute liquid diets, many adult mosquitoes must excrete unwanted aqueous fractions even as they feed. (See the photograph of a feeding Anopheles stephensi: Note that the excreted droplet patently is not whole blood, being far more dilute). As long as they are not disturbed, this permits mosquitoes to continue feeding until they have accumulated a full meal of nutrient solids. As a result, a mosquito replete with blood can continue to absorb sugar, even as the blood meal is slowly digested over a period of several days. Once blood is in the stomach, the midgut of the female synthesizes proteolytic enzymes that hydrolyze the blood proteins into free amino acids. These are used as building blocks for the synthesis of vitellogenin, which are the precursors for egg yolk protein.In the mosquito Anopheles stephensi, trypsin activity is restricted entirely to the posterior midgut lumen. No trypsin activity occurs before the blood meal, but activity increases continuously up to 30 hours after feeding, and subsequently returns to baseline levels by 60 hours. Aminopeptidase is active in the anterior and posterior midgut regions before and after feeding.
Ultimately 3.2% (19/599) of A(H1N1)pdm09 viruses collected between 2009 and 2012 had highly reduced peramivir inhibition due to the H275Y NA mutation.BioCryst Pharmaceuticals submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for intravenous peramivir in December 2013. Peramivir (Rapivab) was approved for intravenous administration in December 2014. References
External links
"Peramivir". Drug Information Portal. U.S. National Library of Medicine. "Peramivir: Requirements for Administration under EUA". Lifehugger. Archived from the original on 2011-07-13. "CDC H1N1 Flu - Termination of the Emergency Use Authorization (EUA) of Medical Products and Devices". U.S. Centers for Disease Control and Prevention (CDC). Clinical trial number NCT00957996 for "Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza" at ClinicalTrials.gov
"A Novel Anti-viral Drug for Influenza, RAPIACTA Launch" (PDF). Shionogi & Co., Ltd. January 26, 2010. Archived from the original (PDF) on 2013-05-22.